Cardiovascular Risk Factors Among Youth With and Without Type 2 Diabetes

Differences and possible mechanisms

NANCY A. WEST, PHD1
RICHARD F. HAMMAN, MD1
ELIZABETH J. MAYER-DAVIS, PHD2
RALPH B. D'AGOSTINO JR., PHD3
SANTICA M. MARCOVINA, PHD4
ANGELA D. LIESE, PHD2
PHILIP S. ZEITLER, MD5
STEPHEN R. DANIELS, MD5
DANA DABELEA, MD1

OBJECTIVE — To compare cardiovascular disease (CVD) risk factors among recently diagnosed youth with type 2 diabetes and nondiabetic youth and investigate whether demographic, behavioral, or metabolic factors might account for observed differences.

RESEARCH DESIGN AND METHODS — Data from 106 type 2 diabetic and 189 nondiabetic multiethnic youth, aged 10–22 years, were analyzed. Prevalence of CVD risk factors were age and race/ethnicity adjusted using direct standardization. Multiple linear regression models were sequentially adjusted for demographic, behavioral (dietary saturated fat intake and physical activity), and metabolic (body adiposity and glycemia) factors to explore possible mechanisms associated with differences in CVD risk factors between the case and control groups.

RESULTS — Compared with control subjects, youth with type 2 diabetes had a higher prevalence of elevated blood pressure, obesity, large waist circumference, low HDL cholesterol, high triglycerides, and high albumin-to-creatinine ratio (P < 0.05 for each risk factor). Type 2 diabetic youth also had higher levels of apolipoprotein B, fibrinogen, interleukin (IL)-6, C-reactive protein, and leptin, lower adiponectin levels, and denser LDL particles (P < 0.05 for each risk factor). Adjustment for BMI, waist circumference, and A1C substantially attenuated differences in the CVD risk factors between the case/control groups, except for fibrinogen and IL-6, which remained significantly higher in type 2 diabetic youth.

CONCLUSIONS — Compared with control youth, type 2 diabetic youth have a less favorable CVD risk factor profile. Adiposity and glycemia are important contributors to differences in CVD risk profiles among type 2 diabetic and control youth. Inflammatory and prothrombotic factors may also play an important role.

Cardiovascular and Metabolic Risk
ORIGINAL ARTICLE

Diabetes Care 32:175–180, 2009

There has been a dramatic increase in the prevalence of type 2 diabetes in children and adolescents during the past two decades (1). Much of the health burden of type 2 diabetes in youth will result from chronic complications, including cardiovascular disease (CVD) (2).

In adults with type 2 diabetes, CVD occurs earlier and is associated with higher mortality compared with the general population (3). Early adult-onset type 2 diabetes (diagnosed age 18–44 years) has been associated with more aggressive CVD than later-onset type 2 diabetes (4), suggesting that CVD complications resulting from type 2 diabetes diagnosed in youth may be even more unfavorable.

Obesity, dyslipidemia, hypertension, and smoking have long been recognized as major risk factors for cardiovascular morbidity and mortality in adults. The typical lipid abnormalities in type 2 diabetic adults are low levels of HDL cholesterol and high levels of triglycerides (5). Studies have recently identified novel lipid abnormalities, including a preponderance of small, dense LDL particles and high levels of apolipoprotein B (apoB) (6). Other novel CVD risk factors indicate systemic inflammation, a prothrombotic state, and endothelial dysfunction, marked by altered levels of interleukin (IL)-6, C-reactive protein (CRP), fibrinogen, adipocytokines, and microalbuminuria.

Given the recent emergence of type 2 diabetes in adolescent populations, the relationship between type 2 diabetes and CVD risk factors among youth has not been well characterized. Although type 2 diabetes itself is considered a risk factor for CVD, we hypothesized that youth with recently diagnosed type 2 diabetes would have a less favorable CVD risk factor profile, excluding diabetes status, compared with nondiabetic youth. We also explored whether measures of adiposity (BMI and waist circumference), hyperglycemia, and behavioral factors (physical activity and dietary intake of saturated fat) may account for observed differences in CVD risk factors between type 2 diabetic and nondiabetic youth.

RESEARCH DESIGN AND METHODS — The study population included participants in the SEARCH Case-Control (SEARCH-CC) study, an ancillary study to the multicenter SEARCH for Diabetes in Youth study (7). SEARCH study participants who were residents of Colorado or South Carolina, aged 10–22 years, and African American, Hispanic, or non-Hispanic whites were invited to participate in the SEARCH-CC study. Because of recruitment from the larger SEARCH study, which had ascertained case subjects diagnosed through...
age 19 years, the oldest of the case subjects had aged to 22 years at the time of recruitment into the SEARCH-CC study. Case subjects were identified using networks of health care providers. Type 2 diabetes was defined by provider diagnosis. In our population, provider classification of diabetes type was previously found to be consistent with the expected clinical and biochemical characteristics, including low frequency of insulin treatment, absence of autoimmune markers, and presence of markers of insulin resistance among youth with type 2 diabetes (8). Overall, 52% of the eligible SEARCH study youth with type 2 diabetes participated in the SEARCH-CC study. Nondiabetic control youth, aged 10–22 years and self-identified as African American, Hispanic, or non-Hispanic white, were recruited from primary care offices in the same geographic areas. Nondiabetic status in the control subjects was confirmed by fasting glucose values. Primary care practices were chosen as the sampling frame for control subjects in order to closely represent the underlying population that gave rise to the type 2 diabetic case subjects. Additional details regarding sampling and recruitment for the SEARCH-CC study have been published (9). Written informed consent was obtained from participants aged ≥18 years, and assent was obtained for participants aged <18 years.

Outcome measures
Blood was drawn after an overnight fast for measurement of total cholesterol, triglycerides, HDL cholesterol, apoB, lipoprotein cholesterol distribution, and calculation of the LDL relative flotation rate ($R_f$), fibrinogen, IL-6, CRP, leptin, and adiponectin. A morning spot-urine sample was collected for measurement of urinary albumin and creatinine for calculation of the albumin-to-creatinine ratio (ACR) (micrograms of albumin per milligram of creatinine). Specimens were processed and shipped within 24 h to the Northwest Lipid Metabolism and Diabetes Research Laboratories for analyses. Measurements of plasma cholesterol, triglycerides, and HDL cholesterol were performed enzymatically on a Hitachi 917 autoanalyzer. LDL cholesterol was calculated by the Friedewald equation for triglyceride concentrations <400 mg/dl (4.52 mmol/L) and by the BetaQuantification procedure for triglycerides ≥400 mg/dl (10). ApoB was measured by a calibrated nephelometric system. The lipoprotein cholesterol distribution used a modification of a previously described technique (11). Urinary albumin was measured by nephelometry, and urinary creatinine was measured by the Jaffe method using a Roche Diagnostics reagent on the Hitachi 917 autoanalyzer. Serum IL-6 concentrations were determined by a capture sandwich immunoassay using a Bio-Plex suspension array system and commercially available reagents from Lincor Research. High-sensitivity CRP and fibrinogen were assayed by a Dade Behring nephelometer using Behring reagents.

Three sitting blood pressure measurements were obtained and averaged. Current smoking status was obtained from self-report. Height was measured to the nearest 0.1 cm by stadiometer. Weight was measured to the nearest 0.1 kg using an electronic scale. Waist circumference was measured to the nearest 0.1 cm using the National Health and Nutrition Examination Survey protocol (12). Anthropometric measurements were taken twice and averaged. Height and weight measurements were used to calculate BMI (kg/m²).

Categorical CVD risk factors were defined as elevated blood pressure (systolic or diastolic blood pressure ≥95th percentile for age, sex, and height or use of antihypertension medication), obesity (BMI ≥95th percentile for age and sex), large waist circumference (≥90th percentile for age and sex), high LDL cholesterol (≥130 mg/dl), low HDL cholesterol (≥35 mg/dl), high triglycerides (≥150 mg/dl), current smoking, and elevated urinary ACR (≥30 μg/mg) (13,14).

Covariates
Race/ethnicity was obtained from self-report using 2000 Census–based questions (15). Fasting A1C was measured by an ion exchange high-performance liquid chromatography instrument. Dietary intake was ascertained using a modified version of the Kids Food Questionnaire (16). Saturated fat intake was calculated as grams per 1,000 kcal. Physical activity was obtained by self-report using questions based on the Youth Risk Behavior Surveillance System (17) and was categorized as the average number of 30-min blocks of moderate-to-vigorous physical activity per day. Self-reported Tanner staging was used to categorize pubertal development using scales ranging from 1 (prepubertal) to 5 (adult).

Statistical analysis
Statistical analyses were performed using PC-SAS (version 9.1). Two sets of analyses were performed. In the first analysis, eight CVD risk factors were categorized to compare risk factor prevalence between type 2 diabetic and nondiabetic youth. The Breslow-Day test was used to evaluate interactions between race/ethnicity and age-group categories (10–15 vs. 16–22 years) and diabetes status. None of the interactions were significant (all $P$ values >0.05); thus, all race/ethnicity and age-groups were included together in the

---

Table 1—Demographic, metabolic, and behavioral characteristics of the study participants

| Characteristic | Type 2 diabetes | Control subjects | $P$ |
|---------------|-----------------|-----------------|-----|
| n             | 106             | 189             |     |
| Female [n (%)]| 73 (69)         | 113 (60)        | 0.12|
| Race/ethnicity [n (%)] |    |                 |     |
| African American | 58 (55)        | 54 (29)         |     |
| Hispanic       | 18 (17)         | 32 (17)         |     |
| Non-Hispanic white | 30 (28)        | 103 (54)        | <0.0001|
| Age (years)    | 15.7 (4.4)      | 14.3 (4.6)      | 0.0001|
| Age at diagnosis (years) | 13.7 (4.0) | — — |     |
| Duration of diabetes (years) | 1.5 (1.4) | — — |     |
| A1C (%)        | 7.4 (2.6)       | 5.2 (0.4)       | <0.0001|
| BMI (kg/m²)    | 35.0 (8.7)      | 23.7 (7.1)      | <0.0001|
| Waist circumference (cm) |     |                 |     |
| Female        | 108.3 (22.1)    | 80.4 (16.4)     | <0.0001|
| Male          | 110.2 (13.9)    | 77.2 (20.3)     | <0.0001|
| Saturated fat [(g)/1,000 kcal] | 14.8 (4.3) | 13.9 (3.6) | 0.005|
| Physical activity* | 4.8 (6.3) | 5.6 (6.3) | 0.17|

Data are means (interquartile range), unless otherwise noted. *Number of 30-min blocks of moderate-to-vigorous physical activity per day.
analyses. Prevalence estimates of CVD risk factors were age and race/ethnicity adjusted using direct standardization. Differences in adjusted prevalence between the case/control groups were evaluated using $\chi^2$ tests.

In a second set of analyses, multiple linear regression models were used to explore differences in CVD risk factors (modeled as continuous variables) between case and control youth. All models were adjusted for demographic factors (age, sex, and race/ethnicity) and then sequentially adjusted for behavioral factors (dietary saturated fat intake and physical activity), adiposity (BMI and waist circumference), and glycemic control (A1C). A final, fully adjusted model included all covariates significantly associated with any CVD risk factor. Comparison of these models allowed investigation of possible mechanisms that may account for differences in specific CVD risk factors between type 2 diabetic and control youth. Nonnormally distributed variables (triglycerides, apoB, IL-6, and CRP) were log transformed for statistical testing, and differences in geometric means are reported to present these variables in their original scale. Estimated differences were positive when values for diabetic youth were greater than for control youth. In separate models for each CVD risk factor, waist circumference only or BMI only were entered into the models instead of both measures to investigate if the distribution of body fat, rather than overall adiposity, might differentially account for discrepant levels among diabetic and control youth.

RESULTS— The analyses included data from type 2 diabetic ($n = 106$) and nondiabetic ($n = 189$) youth, with data on CVD risk factors and covariates. Only diabetic case ($n = 95$) and control ($n = 174$) subjects with complete data on all eight categorized CVD risk factors were used in the analysis comparing CVD risk factor prevalence between the case and control groups. Demographic, metabolic, and behavioral characteristics of the diabetic and control participants are shown in Table 1. Compared with control youth, diabetic youth were slightly older, more likely to be African American, had higher mean BMI and A1C, and had a greater intake of saturated fat per 1,000 kcal. Table 2 shows that youth with diabetes had higher age- and race/ethnicity-adjusted prevalence of elevated blood pressure, obesity, large waist circumference, low HDL cholesterol, high triglycerides, and high ACR. There was little difference between diabetic and control youth in the adjusted prevalence of high LDL cholesterol or current smoking.

Figure 1 shows that of eight categorical CVD risk factors the overall distribution of the total number of CVD risk factors (0, 1, 2, 3, or $\geq 4$) in youth was significantly different ($P < 0.0001$), with a less favorable CVD risk profile for diabetic youth. A total of 60.0% of diabetic youth had three or more CVD risk factors, compared with 13.1% of nondiabetic control youth. Diabetic youth had an average of 2.9 risk factors compared with 1.0 among control youth ($P < 0.0001$).

Table 3 shows the adjusted means and mean differences for each CVD risk factor for diabetic and nondiabetic youth. In model 1, adjusted only for demographic variables, diabetic youth had higher levels of triglycerides, systolic blood pressure, apoB, fibrinogen, IL-6, CRP, and leptin; lower levels of HDL cholesterol and adiponectin; and greater LDL particle density compared with nondiabetic youth. There were no significant differences in mean LDL cholesterol between the groups (data not shown). Adjustment for BMI and waist circumference (model 2) substantially attenuated the differences in HDL cholesterol, systolic blood pressure, CRP, and adiponectin between the two groups. This adjustment for adiposity reversed the direction of the difference in leptin levels between the groups such that control youth had a 38% higher average leptin level than diabetic youth. In model 3, adjustment for A1C significantly attenuated the differences between case and control subjects in apoB, LDL $R_0$, and CRP levels. There was also a substantial lessening of the differences in triglyceride levels (a 58% reduction) with adjustment for A1C. Adjustment for behavioral factors did not significantly influence the mean differences between diabetic and nondiabetic youth for any of the CVD risk factors (data not shown). In model 4, adjustment for all of the demographic and metabolic factors (age, sex, race/ethnicity, BMI, waist circumference, and A1C) resulted in a

### Table 2—Prevalence of CVD risk factors in type 2 diabetic and nondiabetic youth, adjusted for age and race/ethnicity

| CVD risk factor | Type 2 diabetic subjects $(n = 95)$ | Control subjects $(n = 174)$ | $P$ |
|-----------------|-------------------------------------|-----------------------------|-----|
| Elevated blood pressure | 27 (18–36) | 5 (2–8) | $<0.0001$ |
| Obesity | 86 (79–93) | 26 (19–33) | $<0.0001$ |
| Large waist circumference | 82 (74–90) | 22 (16–28) | $<0.0001$ |
| Low HDL cholesterol | 25 (16–34) | 5 (2–8) | $<0.0001$ |
| High triglycerides | 27 (18–36) | 6 (2–10) | $<0.0001$ |
| High ACR | 17 (9–25) | 7 (3–11) | 0.02 |
| High LDL cholesterol | 14 (7–21) | 10 (6–14) | 0.29 |
| Current smoking | 5 (1–9) | 7 (3–11) | 0.56 |

Data are % (95% CI). *Only participants with complete data on these eight CVD risk factors were used in this analysis.
nearly complete attenuation of differences between case and control youth in most of the CVD risk factors, with the notable exceptions of higher fibrinogen and IL-6 levels in diabetic youth and higher CRP levels in nondiabetic youth. In the fully adjusted models, the levels of fibrinogen and IL-6 were 22 and 116% higher, respectively, and CRP levels were

| CVD risk factor                      | Type 2 diabetic subjects | Control subjects | Mean difference* | P   |
|--------------------------------------|--------------------------|------------------|------------------|-----|
| HDL cholesterol (mg/dl)              |                          |                  |                  |     |
| Model 1                              | 42 (39–45)               | 50 (47–53)       | −8               | <0.0001 |
| Model 2                              | 47 (44–50)               | 48 (45–50)       | −1               | 0.5  |
| Model 3                              | 42 (38–45)               | 50 (47–53)       | −8               | <0.0001 |
| Model 4                              | 46 (43–50)               | 48 (46–51)       | −2               | 0.4  |
| Triglycerides (mg/dl)†               |                          |                  |                  |     |
| Model 1                              | 114 (98–133)             | 74 (65–84)       | 40               | <0.0001 |
| Model 2                              | 102 (86–122)             | 78 (68–89)       | 24               | 0.01 |
| Model 3                              | 95 (80–112)              | 78 (68–88)       | 17               | 0.04 |
| Model 4                              | 86 (71–104)              | 81 (71–92)       | 5                | 0.6  |
| Systolic blood pressure (mmHg)       |                          |                  |                  |     |
| Model 1                              | 115 (111–118)            | 107 (104–110)    | 8                | <0.0001 |
| Model 2                              | 110 (106–113)            | 109 (106–112)    | 1                | 0.7  |
| Model 3                              | 114 (110–117)            | 107 (104–110)    | 7                | 0.002 |
| Model 4                              | 109 (105–113)            | 109 (106–112)    | 0                | 0.9  |
| ApoB (mg/dl)†                        |                          |                  |                  |     |
| Model 1                              | 83 (76–92)               | 60 (55–65)       | 23               | <0.0001 |
| Model 2                              | 76 (68–85)               | 61 (57–66)       | 15               | 0.001 |
| Model 3                              | 69 (62–77)               | 63 (58–68)       | 6                | 0.1  |
| Model 4                              | 65 (57–73)               | 64 (60–69)       | 1                | 0.9  |
| LDL particle density (Rf)            |                          |                  |                  |     |
| Model 1                              | 0.262 (0.255–0.268)      | 0.284 (0.278–0.262) | −0.022          | <0.0001 |
| Model 2                              | 0.266 (0.259–0.274)      | 0.282 (0.276–0.288) | −0.016          | 0.001 |
| Model 3                              | 0.274 (0.266–0.281)      | 0.280 (0.275–0.286) | −0.007          | 0.1  |
| Model 4                              | 0.277 (0.269–0.285)      | 0.279 (0.274–0.285) | −0.002          | 0.6  |
| Fibrinogen (mg/dl)                   |                          |                  |                  |     |
| Model 1                              | 442 (420–465)            | 310 (292–328)    | 132              | <0.0001 |
| Model 2                              | 410 (387–433)            | 319 (303–336)    | 91               | <0.0001 |
| Model 3                              | 428 (400–455)            | 314 (295–332)    | 114              | <0.0001 |
| Model 4                              | 395 (369–422)            | 323 (306–340)    | 72               | <0.0001 |
| IL-6 (pg/dl)†                        |                          |                  |                  |     |
| Model 1                              | 7.9 (5.2–11.1)           | 2.9 (2.0–4.0)    | 5.0              | <0.0001 |
| Model 2                              | 6.8 (4.2–11.0)           | 3.0 (2.1–4.2)    | 3.8              | 0.005 |
| Model 3                              | 7.3 (4.3–12.3)           | 2.9 (2.1–4.1)    | 4.4              | 0.004 |
| Model 4                              | 6.5 (3.7–11.4)           | 3.0 (2.1–4.3)    | 3.5              | 0.03  |
| CRP (mg/dl)†                         |                          |                  |                  |     |
| Model 1                              | 0.20 (0.12–0.33)         | 0.07 (0.04–0.10) | 0.13             | 0.0004 |
| Model 2                              | 0.07 (0.04–0.12)         | 0.09 (0.06–0.13) | −0.02            | 0.5  |
| Model 3                              | 0.12 (0.06–0.22)         | 0.08 (0.05–0.12) | 0.04             | 0.2  |
| Model 4                              | 0.05 (0.03–0.08)         | 0.10 (0.07–0.14) | −0.05            | 0.03  |
| Leptin (ng/dl)                       |                          |                  |                  |     |
| Model 1                              | 24 (20–29)               | 15 (11–18)       | 9                | 0.0004 |
| Model 2                              | 13 (9–17)                | 18 (15–20)       | −5               | 0.03  |
| Model 3                              | 26 (20–32)               | 14 (10–18)       | 12               | 0.0009 |
| Model 4                              | 15 (10–19)               | 17 (15–20)       | −2               | 0.3  |
| Adiponectin (μg/dl)                  |                          |                  |                  |     |
| Model 1                              | 10.7 (9.0–12.3)          | 14.0 (12.6–15.3) | −3.3             | 0.0008 |
| Model 2                              | 12.4 (10.6–14.3)         | 13.5 (12.1–14.8) | −1.0             | 0.3  |
| Model 3                              | 10.8 (8.7–12.9)          | 13.9 (12.5–15.3) | −3.1             | 0.01  |
| Model 4                              | 12.4 (10.3–14.6)         | 13.5 (12.1–14.8) | −1.0             | 0.4  |

Data are means (95% CI). Model 1: adjusted for age, sex, and race/ethnicity. Model 2: model 1 plus BMI plus waist circumference. Model 3: model 1 plus A1C. Model 4: model 1 plus BMI, waist circumference, and A1C. *Estimated differences are positive when values for diabetic youth are more than control youth. †Geometric means are reported.
50% lower for diabetic youth compared with control subjects.

Models evaluating waist circumference and BMI separately revealed similar results to models including both waist circumference and BMI, with the exception that waist circumference alone did not significantly attenuate the differences in leptin levels between the case/control subjects (data not shown). Including Tanner stage in the regression models in addition to age had minimal effect on the case/control subject difference in any CVD risk factor levels.

CONCLUSIONS — We found that youth with type 2 diabetes and a relatively short diabetes duration (average 1.5 years) have a higher prevalence of many CVD risk factors, including obesity and central fat deposition, elevated blood pressure, dyslipidemia, and elevated ACR, compared with nondiabetic youth of similar age, sex, and race/ethnicity. Moreover, youth with diabetes tend to have a cluster of multiple CVD risk factors, on average 2.9 vs. 1.0 in the control group. Data from the Bogalusa Heart Study (18) showed that the risk of fibrous plaques in the coronary arteries in youth with three or four CVD risk factors was three to eight times higher than the risk with zero, one, or two risk factors.

Our data show that youth with type 2 diabetes have an atherogenic dyslipidemia characteristic of adults with type 2 diabetes, including low HDL cholesterol, high triglycerides, and apoB and increased levels of LDL particle density. There were no significant differences in LDL cholesterol between case and control youth in our study. Elevated levels of apoB in the presence of normal LDL cholesterol levels have been associated with acute myocardial infarction in adults (19). Elevated apoB levels in the presence of normal LDL cholesterol levels may be explained by the increased concentration of triglyceride-rich apoB-containing lipoproteins and by the presence of dense LDL that is enriched in apoB relative to its cholesterol content. The association between type 2 diabetes and hypertension is well established in adults, and our findings support a similar relationship in youth.

Our findings suggest that adiposity and glycemic control account for much of the association between type 2 diabetes and an unfavorable CVD risk factor profile in youth. Excess adiposity, particularly visceral abdominal obesity, is a well-known risk factor for a cluster of metabolic abnormalities, including insulin resistance, dyslipidemia, and hypertension, and is in turn associated with the development of CVD. Consistent with data in adults (20), we found that adiposity, as measured by BMI and waist circumference, has a strong effect on differences in HDL cholesterol, triglycerides, and blood pressure levels between diabetic and nondiabetic youth.

Accumulating evidence indicates that adipose tissue releases a number of bioactive mediators that play an important role in the regulation of metabolic, inflammatory, and thrombotic pathways that are associated with CVD risk (21). Most of these factors, including leptin, fibrinogen, IL-6, and CRP, are overproduced with obesity. Conversely, plasma levels of adiponectin, an insulin-sensitizing cytokine, are downregulated during obesity. We observed significantly higher levels of CRP, IL-6, fibrinogen, and leptin and lower levels of adiponectin in diabetic youth than in healthy control subjects. Consistent with a key role of obesity in the dysregulation of these adipocytokines and inflammatory factors in youth with type 2 diabetes, case-control differences disappeared (for adiponectin and leptin) or were even reversed (for CRP) on adjustment for adiposity. Nevertheless, fibrinogen and IL-6 remained significantly elevated in diabetic youth relative to nondiabetic youth, independent of demographic factors, adiposity, and glycemia, suggesting potential independent effects of fibrinogen and IL-6 on type 2 diabetes-related CVD risk in youth.

Although obesity is a major contributor to cardiometabolic risk, prospective studies suggest a possible independent effect of hyperglycemia (22). Hyperglycemia accelerates the formation of advanced glycation end products, which can lead to atherothrombotic endothelial damage. Our results suggest smaller effects of hyperglycemia, relative to adiposity, on CVD risk profiles in youth with diabetes. However, the present data suggest that hyperglycemia may have important effects on lipoprotein risk factors, including apoB and LDL particle size. Previous data from the SEARCH study indicated that both apoB levels and LDL density increased significantly with increasing A1C in youth with either type 1 or type 2 diabetes (23). Also, insulin therapy in adults with type 2 diabetes was shown to significantly reduce apoB levels (24).

This study has several limitations. The cross-sectional data limits our ability to definitively identify which factors and pathways account for the unfavorable CVD risk profile observed in diabetic youth compared with nondiabetic youth. Also, the case-control design has an inherent limitation of potential selection bias; however, comparisons between eligible type 2 diabetic case subjects that did and did not participate in this study revealed no significant differences in diabetes duration, BMI z-scores, or waist circumference ($P > 0.05$ for each comparison). Additionally, there is a lack of consensus regarding specific criteria and cutoff values for CVD risk factors, particularly in youth. Despite this limitation, our findings that the mean values and prevalence for a majority of CVD risk factors are significantly higher in type 2 diabetic youth is an important and timely observation about the potential burden of comorbidities in this population, especially given that many CVD risk factors encountered in youth track from childhood into adulthood (25).

In summary, when compared with youth without diabetes, type 2 diabetic youth have a higher prevalence of many and multiple CVD risk factors. Adiposity and glycemia are both independent and interdependent contributors to a less favorable CVD risk profile for diabetic youth. Inflammatory and coagulation/prothrombotic factors may also play an important role. Because an earlier age of onset of type 2 diabetes will likely increase the lifetime incidence of CVD complications, early prevention and treatment strategies aimed at reducing the prevalence of CVD risk factors in these youth are needed.

Acknowledgments — The SEARCH-CC study was funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK: R01 DK09184).

No potential conflicts of interest relevant to this article were reported.

References
1. Pinhas-Hamiel O, Zeitler P: The global spread of type 2 diabetes mellitus in children and adolescents. J Pediatr 146:693–700, 2005
2. Milicicvic Z, Raz I, Beattie SD, Campagne BN, Sarwat S, Grönnia K, Kowalski I, Galic E, Tan M, Hanefeld M: Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia. Diabetes Care 31 (Suppl. 2):S155–S160, 2008
CVD risk in youth with and without diabetes

3. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC Jr, Sowers JR: Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 100:1134–1146, 1999

4. Hillier TA, Pedula KL: Complications in young adults with early-onset type 2 diabetes: losing the relative protection of youth. Diabetes Care 26:2999–3005, 2003

5. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106:3143–3421, 2002

6. Grundy SM: Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol 47:1093–1100, 2006

7. SEARCH Study Group: SEARCH for Diabetes in Youth: a multicenter study of the prevalence, incidence and classification of diabetes mellitus in youth. Control Clin Trials 25:458–471, 2004

8. Dabelea D, Bell RA, D’Agostino RB Jr, Imperatore G, Johansen JM, Linder B, Liu LL, Loots B, Marcovina S, Mayer-Davis EJ, Pettit DJ, Waitefelder B: Incidence of diabetes in youth in the United States. JAMA 297:2716–2724, 2007

9. Mayer-Davis EJ, Dabelea DM, Johansen JM, Pihoker C, Rodriguez BL, Thomas J, Williams D: Dietary intake among youth with diabetes: the SEARCH for Diabetes in Youth Study. J Am Diet Assoc 106:689–697, 2006

10. Warnick GR, Nguyen T, Bergelin RO, Wahl PW, Albers JJ: Lipoprotein quantification: an electrophoretic method compared with the Lipid Research Clinics method. Clin Chem 28:2116–2120, 1982

11. Purnell JQ, Marcovina SM, Hokanson JE, Kennedy H, Cleary PA, Stieles MW, Brunzell JD: Levels of lipoprotein(a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM: results from follow-up in the Diabetes Control and Complications Trial. Diabetes 44:1218–1226, 1995

12. Fernandez JR, Redden DT, Pietrobelli A, Allison DB: Waist circumference percentiles in nationally representative samples of African-American, European-American, and Mexican-American children and adolescents. J Pediatr 145:439–444, 2004

13. Duncan GE, Li SM, Zhou XH: Prevalence and trends of a metabolic syndrome phenotype among U.S. Adolescents, 1999–2000. Diabetes Care 27:2438–2443, 2004

14. Peterson K, Silverstein J, Kaufman F, Warren-Boulton E: Management of type 2 diabetes in youth: an update. Am Fam Physician 76:658–664, 2007

15. Office of Management and Budget (U.S.): Revisions to the Standards for Classification of Federal Data on Race and Ethnicity. 62 Federal Register 58781(1997).

16. Mayer-Davis EJ, Nicholls M, Liese AD, Bell RA, Dabelea DM, Johansen JM, Pihoker C, Rodriguez BL, Thomas J, Williams D: Dietary intake among youth with diabetes: the SEARCH for Diabetes in Youth Study. J Am Diet Assoc 106:689–697, 2006

17. Kann L, Kinchen SA, Williams BI, Ross JG, Lowry R, Grunbaum JA. Kolbe LJ: Youth risk behavior surveillance—United States, 1999. MMWR CDC Surveill Summ 49:1–32, 2000

18. Berenson GS, Srinivasan SR, Bao W, Newman WP 3rd, Tracy RE, Wattigney WA: Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults: the Bogalusa Heart Study. N Engl J Med 338:1650–1656, 1998

19. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E: High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358:2026–2033, 2001

20. Smith SC Jr.: Multiple risk factors for cardiovascular disease and diabetes mellitus. Am J Med 120:S3–S11, 2007

21. Van Gaal LF, Mertens IL, De Block CE: Mechanisms linking obesity with cardiovascular disease. Nature 444:875–880, 2006

22. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405–412, 2000

23. Albers JJ, Marcovina SM, Imperatore G, Snively BM, Stafford J, Fujimoto WY, Mayer-Davis EJ, Pettiti DB, Pihoker C, Dolan L, Dabelea DM: Prevalence and determinants of elevated apolipoprotein B and dense low-density lipoprotein in youths with type 1 and type 2 diabetes. J Clin Endocrinol Metab 93:735–742, 2008

24. Taskinen MR, Kuusi T, Helve E, Nikkila EA, Yki-Jarvinen H: Insulin therapy induces antiatherogenic changes of serum lipoproteins in noninsulin-dependent diabetes. Arteriosclerosis 8:168–177, 1988

25. Charakida M, Deanfield JE, Halcox JP: Childhood origins of arterial disease. Curr Opin Pediatr 19:538–545, 2007